-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Enterprise News] In recent years, NHU has continued to increase R&D investmen.
Data shows that in the first half of 2022, the company's R&D investment increased by more than 30% year-on-year, close to the level of 2020, accounting for 144% of revenu.
It is reported that the company's Oxelidine Fumarate Injection has been reported for production and is under revie.
Enhua Pharmaceutical's Oxelidine Fumarate Injection was accepted for marketing authorization in January this yea.
The product is suitable for acute pain in adult patients requiring intravenous opioids and poor alternative therap.
The data show that Oxelidine Fumarate Injection is a novel small-molecule G protein-biased μ-opioid receptor (MOR) agonist created by American Trevena Company (First-in-class), which preferentially activates the analgesic effec.
At the same time, it can reduce the activation of signaling pathways that cause adverse reaction.
Oxelidine Fumarate Injection (trade name: OLINVYKR) was approved in the United States in 2020 for the treatment of moderate to severe acute pain in adult patients requiring intravenous opioid.
Nhwa Pharmaceutical said that the company has strong market competitiveness in the field of anesthesia, and the approval of Oxelidine Fumarate Injection in the future will enrich the company's product pipeline in the field of anesthesia, which is conducive to enhancing the company's core competition It will have a positive impact on the company's future performance improvemen.
Enhua Pharmaceutical stated at the 2021 annual performance briefing that the product is expected to receive production approval around the end of 2022.Regarding market space expectations, the company expects that the product can achieve higher income in 2-3 years after its launch, and can reach more than 1 billion in the long ru.
It is reported that as of now, Nhua Pharmaceutical has 7 varieties under review under new classification, and 4 are expected to be Oxelidine Fumarate Injection, Midazolam Hydrochloride Syrup, and Tapentadol Hydrochloride Sustained-Release Tablet.
Take the first cop.
In addition, the data shows that NHU has more than 70 research projects, including 16 consistency evaluation projects, 38 key generic drug research projects, and more than 20 innovative drug project.
In answering questions from investors recently, Nhwa Pharmaceutical stated that with the successive listing of high-barrier generic drugs (such as fentanyl products, oxycodone, RTV-130, et.
), the company's future operating income and profits will be achieve rapid growt.
Recently, Nhua Pharmaceutical announced its performance report for the first half of 202 The report shows that in the first half of the year, the company's operating income increased by 3% year-on-year to 001 billion yuan, and the net profit attributable to the parent increased by 91% year-on-year to 448 million yua.
Net profit attributable to the parent increased by 02% year-on-year to 450 million yua.
Among them, the proportion of anesthesia products further increased, and the product structure improved rapidl.
In the first half of the year, its revenue from anesthesia products increased by 188% year-on-year to 978 million yua.
Some institutions predict that the company's performance in 2022-24 will be 87, 01, and 20 yuan per share, respectivel.
Considering the rapid increase in volume of the company's anesthetic preparation products, the product categories are gradually complete, the product structure is rapidly improved, and combined with the attributes of the anesthetic industry; due to the large adjustment range of the industry as a whole, with reference to the valuation of comparable companies, the reasonable value is 152 yuan / share, corresponding to 21 times PE in 22 years , maintain a "buy" ratin.
It is reported that in the past 90 days, the company has been rated by 8 institutions, 7 with buy rating and 1 with overweight ratin.
Disclaimer: Under no circumstances shall the information or opinions expressed in this article constitute investment advice to anyone
Data shows that in the first half of 2022, the company's R&D investment increased by more than 30% year-on-year, close to the level of 2020, accounting for 144% of revenu.
It is reported that the company's Oxelidine Fumarate Injection has been reported for production and is under revie.
Enhua Pharmaceutical's Oxelidine Fumarate Injection was accepted for marketing authorization in January this yea.
The product is suitable for acute pain in adult patients requiring intravenous opioids and poor alternative therap.
The data show that Oxelidine Fumarate Injection is a novel small-molecule G protein-biased μ-opioid receptor (MOR) agonist created by American Trevena Company (First-in-class), which preferentially activates the analgesic effec.
At the same time, it can reduce the activation of signaling pathways that cause adverse reaction.
Oxelidine Fumarate Injection (trade name: OLINVYKR) was approved in the United States in 2020 for the treatment of moderate to severe acute pain in adult patients requiring intravenous opioid.
Nhwa Pharmaceutical said that the company has strong market competitiveness in the field of anesthesia, and the approval of Oxelidine Fumarate Injection in the future will enrich the company's product pipeline in the field of anesthesia, which is conducive to enhancing the company's core competition It will have a positive impact on the company's future performance improvemen.
Enhua Pharmaceutical stated at the 2021 annual performance briefing that the product is expected to receive production approval around the end of 2022.Regarding market space expectations, the company expects that the product can achieve higher income in 2-3 years after its launch, and can reach more than 1 billion in the long ru.
It is reported that as of now, Nhua Pharmaceutical has 7 varieties under review under new classification, and 4 are expected to be Oxelidine Fumarate Injection, Midazolam Hydrochloride Syrup, and Tapentadol Hydrochloride Sustained-Release Tablet.
Take the first cop.
In addition, the data shows that NHU has more than 70 research projects, including 16 consistency evaluation projects, 38 key generic drug research projects, and more than 20 innovative drug project.
In answering questions from investors recently, Nhwa Pharmaceutical stated that with the successive listing of high-barrier generic drugs (such as fentanyl products, oxycodone, RTV-130, et.
), the company's future operating income and profits will be achieve rapid growt.
Recently, Nhua Pharmaceutical announced its performance report for the first half of 202 The report shows that in the first half of the year, the company's operating income increased by 3% year-on-year to 001 billion yuan, and the net profit attributable to the parent increased by 91% year-on-year to 448 million yua.
Net profit attributable to the parent increased by 02% year-on-year to 450 million yua.
Among them, the proportion of anesthesia products further increased, and the product structure improved rapidl.
In the first half of the year, its revenue from anesthesia products increased by 188% year-on-year to 978 million yua.
Some institutions predict that the company's performance in 2022-24 will be 87, 01, and 20 yuan per share, respectivel.
Considering the rapid increase in volume of the company's anesthetic preparation products, the product categories are gradually complete, the product structure is rapidly improved, and combined with the attributes of the anesthetic industry; due to the large adjustment range of the industry as a whole, with reference to the valuation of comparable companies, the reasonable value is 152 yuan / share, corresponding to 21 times PE in 22 years , maintain a "buy" ratin.
It is reported that in the past 90 days, the company has been rated by 8 institutions, 7 with buy rating and 1 with overweight ratin.
Disclaimer: Under no circumstances shall the information or opinions expressed in this article constitute investment advice to anyone
